Seaside Therapeutics is focused on developing drugs targeting the mGluR5 pathway to treat fragile X syndrome and autism. Research indicates that mGluR5 negative allosteric modulators (NAMs) normalize the excessive protein synthesis which may give rise to symptoms associated with fragile X syndrome. STX107, an mGluR5 NAM, could potentially restore this imbalance. For more information, please see the mGluR pathway technical primer.